Nimodipine, a calcium entry blocker, was ad ministered in increasing doses of 0.1-3.0 fLg kg-I min-I to six dogs after they had recovered consciousness from a surgical preparation that was conducted under general anesthesia and while they were under the int1uence of total spinal anesthesia. CBF was measured with a sagittal sinus outt1ow technique and CMR02 was calculated as the product of CBF and the arteriovenous O2 difference.
creatine, ATP, lactate, or energy charge when compared with six control dogs. It has previously been reported that nimodipine increases the CBF in global ischemia with a potentially beneficial effect on the neurological outcome. With no effect on normal CBF or metabolism, this suggests that nimodipine may be useful in a variety of ischemic situations without fear of either a steal phenom enon or untoward effects on intracranial pressure. Key Words: Cerebral blood t1ow-Cerebral metabolism-Ni modipine.
Ca 2 + is also a mediator of normal muscle tone in the vasculature. Thus, the question arises of whether nimodipine increases only ischemic blood flow or is a general cerebral vasodilator. If the drug increases blood flow only in ischemic areas, and possibly also prevents deleterious tissue reactions, it might be of benefit in numerous situations of ce rebral ischemia and hypoxia. If, on the other hand, nimodipine is a general cerebral vasodilator, it might be deleterious to a patient with increased in tracranial pressure OCP) or cause a steal phenom enon in regional cerebral ischemia.
The literature so far is contradictory. Harper et al. (1981) , Kazda et al. (1982) , McCalden et al. (1984) , and Mohammed et al. (1984 and Mohammed et al. ( , 1985b found an increase in non ischemic CBF with nimodipine, while Harris et al. (1982) found an increase in CBF only in an open-skull model, and not if the skull was closed. Nimodipine, furthermore, did not cause a steal phenomenon during focal ischemia, but improved CBF in the ischemic area after middle cerebral artery occlusion in primates (Harris et aI., 1982) and rats (Mohammed et aI., 1985a) , indicating that the drug caused cerebral vasodilation only in the ischemic area.
Interpretation of these studies is complicated by the fact that most were done under the influence of general anesthetics that affect the CBF. Mohammed et al. (l985b) reported an increase in CBF also in awake rats, while Kanda and Flaim (1986) found that nimodipine increased CBF only in barbiturate anesthetized but not in awake rats. The doses used in that study were 0.4, 1.6, and 4.0 f.Lg kg -I min -I.
We have studied the effects of clinically relevant infusion rates of nimodipine in awake dogs where pain and stress responses were blocked by a combi nation of local and spinal anesthesia (Steen et aI., 1983) . Blood gases were determined at 37°C by electrodes (Instrumentation Laboratory Inc., Lexington, MA, o .S.A.). Blood oxygen contents were calculated from measurements of oxyhemoglobin concentration (CO oximeter; Instrumentation Laboratory) and oxygen ten sion (Theye, 1970) . CMR02 was calculated as the product of the CBF and the arterial-sagittal sinus blood O2 con tent difference. To tal spinal anesthesia was achieved with 2 ml 0.5% bupivacaine hydrochloride via a lumbar sub arachnoid needle, and the surgical head wound was infil trated with 20 ml 0.25% bupivacaine. The eyes were taped and the ears were plugged with cotton before the halothane-nitrous oxide anesthesia was discontinued.
MATERIALS AND METHODS
When end-tidal nitrous oxide was <3% and halothane <0.05%, as measured by a mass spectrometer (Beckman LB-2 medical gas analyzer; Beckman Instruments, Inc., Vol, 6, No.6, 1986 Fullerton, CA, U.S.A.), control measurements were made.
Thereafter, a continuous intravenous infusion of nimo dipine, 0.1 JLg kg-I min-I, was administered for 15 min with a full set of measurements at 7.5 and 15 min. The dose was then increased to 0.3, 1.0, and 3.0 JLg kg-I min -I every 15 min with new measurements taken every 7.5 min. After a total dose of 66 JLg kg-I, the skull was opened, the dura overlying the hemispheres was excised, and cortical biopsies were taken by a technique that de posits a sample of the brain (200-400 mg) into liquid ni trogen within I s (Kramer et aI., 1968) . The dogs were then killed with an injection of potassium chloride. The tissue was stored at -76°C and prepared for analysis in a refrigerated box at -25°C as described by Folbergrova et al. (1972) . (Atkinson, 1968) . The cerebral metabolite levels were compared with previously published control values (Roald et aI., 1986) by an unpaired t test. CBF, CMR02,
and ICP values were analyzed with a nonparametric two way analysis of variance (Friedman's test).
RESULTS
As there were no significant differences between the values found after 7. 5 and 15 min of nimodipine infusion at any dosage, only the IS-min values are reported.
Systemic variables are presented in Ta ble I.
There were no significant changes in the blood gases throughout the study, except for a slight in crease in the Paco 2 with a corresponding decrease in pH. The MABP decreased as the nimodipine dosage was increased, corresponding with a par allel increase in the heart rate, with sinus rhythm throughout the experiment.
There were no significant changes in the CBF, CMR0 2 , or ICP ( Fig. 1; Ta ble 1 ). The EEG showed normal a-activity throughout the study.
There were no significant differences in the EC or in the ATP, PCr, lactate, or glucose levels. There was a significant reduction in the pyruvate level with a parallel increase in the lactate/pyruvate ratio ( Table 2) . (1984) reported an increase in the CBF with doses of nimodipine ranging from 0. 1 to 1,000 f-lg kg-I min -I i. v. in primates. Kazda et al. (1982) also found CBF increases after 1-100 f-lg kg-I as bolus injections into dogs and cats. Mohammed et al. (1984) reported a significant increase in CBF in the cortex, but minimal changes in caudal areas during nimodipine infusion, 1-4 f-lg kg-I min-I, in rats.
The reason for these discrepancies in results cannot be firmly established, but they might be due to the fact that these studies were performed under general anesthesia. Recently Kanda and Flaim (1986) reported that nimodipine in doses of 0.4-4.0 f-lg kg -I min -I caused an increase in CBF in anes thetized rats but had no effect in awake rats. In the studies by Harper et al. (1981) , anesthesia was in duced with thiopental, 7.5 mg kg -I, and maintained with 70% N20 and phencyclidine, 0.01 f-lg kg-I min -I. All of these drugs probably affect the CBF.
A bolus dose of thiopental causes cerebral vaso constriction that gradually subsides, while N20 is a cerebral vasodilator ). We have no information on the effects of phencyclidine, but it is the mother compound of ketamine, which is a potent cerebral vasodilator in the dog (Dawson et aI., 1971) . Dawson et ai. further showed that when thiopental, 5 mg kg-I, is admin- Roald et al. (1986) , where biopsies were taken after the same surgical and anesthetic procedures without any additional drugs.
bp<0.05. the brain is not influenced by a general anesthetic, have given very consistent and stable CBF values (Steen et aI., 1983; Roald et aI., 1986) . The dogs were free from pain after locally infiltrated bupiva caine, and any stress response that could have af fected CBF/CMR02 (Carlsson et aI., 1977) was blocked by the spinal anesthesia, which blocks the whole sympathetic system including the adrenals.
There was a slight increase in the Paco2 during the study, but this cannot explain the lack of an effect by nimodipine on the CBF. If anything, the increase in the Paco2 should have caused an increase in CBF.
If nimodipine ameliorates the effects of cerebral vasospasm and increases CBF during ischemia (Harris et aI., 1982; Allen et aI., 1983; Steen et aI., 1983 ) but fails to influence nonischemic CBF, it should not cause a steal phenomenon and thus would not be contraindicated during regional isch emia. This is in agreement with the results of Harris A cerebral vasodilator that also reduces MABP is contraindicated in patients with increased ICP ; this will cause further increases in ICP with a parallel reduction in the perfusion pressure, which likely would more than offset the decrease in cerebral vascular resistance, thus giving a paradoxical de crease in CBF. If there is only a localized increase in ICP due to a regional process, and nimodipine causes vasodilation only in the ischemic area and not in the rest of the brain, it is possible that CBF in the ischemic region might increase despite a pos sible decrease in the cerebral perfusion pressure.
If, on the other hand, the whole brain is ischemic owing to a high ICP, vasodilation could lead to a deleterious further increase in the ICP.
There were apparently few metabolic effects of nimodipine. The CMR02 stayed constant, and there were no significant changes in the ATP, PCr, glucose, or lactate levels or the EC. There was a decrease in the pyruvate level, the significance of which is unknown.
J Cereb Blood Flow Metab, Vol. 6, No.6, 1986 In conclusion nimodipine in clinical doses did not influence the normal CBF. Thus, its potential vaso dilatory effects in a variety of ischemic situations may be particularly beneficial since an intracerebral steal phenomenon should not occur.
